PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans

References

• Baumann G, Shaw MA, Amburn K. Circulating growth hormone-binding proteins. Journal of Endocrinology Investigation 1994; 17: 67–81
   PubMed Web of Science ®Google Scholar
• Beal S, Sheiner L. NONMEM users guides. NONMEM project group, University of California, San Francisco, CA 1992
   Google Scholar
• Catalina PF, Andrade MA, Garcia-Mayor RV, Mallo F. Altered GH elimination kinetics in type 1 diabetes mellitus can explain the elevation in circulating levels: Bicompartmental approach. Journal of Clinical Endocrinology and Metabolism 2002; 87: 1785–1790
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M, Devesa J, Arce VM. Proteolytic processing of human growth hormone (GH) by rat tissues in vitro: Influence of sex and age. Journal of Endocrinology Investigation 2000; 23: 748–754
   PubMed Web of Science ®Google Scholar
• Haffner D, Schaefer F, Girard J, Ritz E, Mehls O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. Journal of Clinical Investigation 1994; 93: 1163–1171
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Delivery 2006; 13: 399–409
   PubMed Web of Science ®Google Scholar
• Hansen TK, Gravholt CH, Orskov H, Rasmussen MH, Christiansen JS, Jorgensen JO. Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. Journal of Clinical Endocrinology and Metabolism 2002; 87: 4691–4698
   PubMed Web of Science ®Google Scholar
• Hattori N, Shimatsu A, Kato Y, Imura H. Growth hormone and growth hormone-binding protein in human urine. Kidney International 1990; 37: 951–954
   PubMed Web of Science ®Google Scholar
• Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. Journal of Clinical Endocrinology and Metabolism 2005; 90: 6431–6440
   PubMed Web of Science ®Google Scholar
• Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods in Programs in Biomedicine 1999; 58: 51–64
   PubMed Web of Science ®Google Scholar
• Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. Journal of Clinical Endocrinology and Metabolism 2004; 89: 4532–4537
   PubMed Web of Science ®Google Scholar
• Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ. Albutropin: A growth hormone–albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. European Journal of Pharmacology 2002; 456: 149–158
   PubMed Web of Science ®Google Scholar
• Root AW, Root MJ. Clinical pharmacology of human growth hormone and its secretagogues. Current Drug Targets and Immune Endocrine Metabolic Disorders 2002; 2: 27–52
   PubMedGoogle Scholar
• Turyn D, Dominici FP, Sotelo AI, Bartke A. Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. Growth Hormones and IGF Research 1998; 8: 389–396
   PubMed Web of Science ®Google Scholar
• Uchida H, Banba S, Wada M, Matsumoto K, Ikeda M, Naito N, Tanaka E, Honjo M. Analysis of binding properties between 20 kDa human growth hormone (hGH) and hGH receptor (hGHR): The binding affinity for hGHR extracellular domain and mode of receptor dimerization. Journal of Molecular Endocrinology 1999; 23: 347–353
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2002; 87: 5737–5745
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Johnson ML, Faunt LM, Mercado M, Baumann G. Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications. Journal of Clinical Investigation 1993; 91: 629–641
   PubMed Web of Science ®Google Scholar
• Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metabolism and Disposition 2007; 35: 9–16
   PubMed Web of Science ®Google Scholar